Continuous femoral nerve block as pain management following total knee arthroplasty: a systematic review.
Systematic Review
The present systematic review evaluated the current level of I evidence on continuous femoral nerve block (FNB) as pain management following total knee arthroplasty (TKA), comparing different drugs./r/nThis study followed the 2020 PRISMA guidelines. PubMed, Embase and Web of Science were accessed in November 2024. All clinical studies concerning continuous FNB for pain management following TKA were considered./r/nData from 22 RCTs were retrieved. The drugs included in the analyses were levobupivacaine, bupivacaine and ropivacaine in isolation or combined with prilocaine or dexmedetomidine. A statistically significant difference was found in VAS at rest in postoperative day (POD) 0 (p < 0.01): the bupivacaine group demonstrated the highest values, and the ropivacaine combined with dexmedetomidine group had the lowest values. No other statistically significant difference in VAS at rest was found for any group in POD 1, 2, and 3 (p = 0.1, p = 0.1, and p = 0.4, respectively). The groups receiving ropivacaine combined with dexmedetomidine and prilocaine had the lowest values of VAS during activity in POD2 (p < 0.01), while in POD3 the groups receiving ropivacaine combined with prilocaine and the bupivacaine one had the lowest values (p < 0.01). No significant difference was found in VAS during activity between any group in POD 0 (p = 0.4) and POD 1 (p = 0.3)./r/nRopivacaine combined with dexmedetomidine might be the best compound for continuous femoral nerve block to manage pain following TKA during the first PODs. Further high-quality investigations are necessary to validate these findings in clinical settings.
